跳轉至內容
Merck
全部照片(1)

文件

G004431

LC/MS Analysis of Clenbuterol In Plasma on Astec® CHIROBIOTIC® T with Phospholipid Removal using HybridSPE® Phospholipid

application for SPE, application for LC-MS

登入查看組織和合約定價


About This Item

技術

LC/MS: suitable
solid phase extraction (SPE): suitable

測試參數

sample preparation: SPE (Solid Phase Extraction)
sample/matrix: rat plasma spiked with clenbuterol enantiomers at 10 ng/mL
SPE well plate: HybridSPE-Precipitation 96-well Plate, 50 mg/well (575656-U)
sample addition: 100 μL spiked rat plasma followed by 300 μL 1% formic acid in acetonitrile. Mix by vortexing the HybridSPE-PPT plate briefly.
elution: apply vacuum
column: CHIROBIOTIC T, 10 cm x 2.1 mm I.D., 5 μm particles (12018AST)
mobile phase: 10 mM ammonium formate in methanol
flow rate: 0.3 mL/min
column temp.: 30 °C
detector: ABI 3200 QT; ESI(+), MRM: 184/104 m/z (phospholipids); 277.2/203.1 m/z (clenbuterol)
injection: 10 μL

適合性

application for LC-MS
application for SPE

應用

clinical
forensics and toxicology
pharmaceutical (small molecule)

應用

The HybridSPE method provides significant improvement in LC-MS baseline.

法律資訊

Astec is a registered trademark of Merck KGaA, Darmstadt, Germany
CHIROBIOTIC is a registered trademark of Sigma-Aldrich Co. LLC
HybridSPE is a registered trademark of Merck KGaA, Darmstadt, Germany

Choose from one of the most recent versions:

分析證明 (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務